Horizon Therapeutics plc Reports Third-Quarter 2022 Financia

Third-Quarter 2022 Results: -- Net Sales of $925.4 Million -- -- GAAP Net Income of $135.8 Million; Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones

Related Keywords

United States , Germany , Japan , Austria , Ireland , Canada , Russia , France , Ukraine , Irish , American , Geoff Curtis , Tim Walbert , Tina Ventura , Ray Gordon , Erin Linnihan , Instagram , Linkedin , Twitter , Companies That Care , Share Repurchase Program , Subcutaneous Sc Administration Trial , American College Of Rheumatology , Nasdaq , Key Clinical Development Programs , Facebook , Development For The Treatment Of Autoimmune Diseases , Research In Multiple Sclerosis , Clinical Program , Apotex Inc , Division Of Corporation , Company Board Of Directors , Drug Administration , American Academy Of Ophthalmology , American Thyroid Association , Alkem Laboratories Inc , Exchange Commission , European Alliance Of Associations , Brazil National Health Surveillance Agency , Seramount Best Companies For Dad , European Committee For Treatment , Corporate Affairs , Company Global Expansion , Which Includes , Net Sales , Peak Annual Net Sales Expectations , Sales Guidance , Expect Full Year , Sales Percentage Growth , Sales Growth Expectations , Annual Net Sales Expectations , Company Highlights , Low Clinical Activity Score , Thyroid Eye Disease , Topline Results Expected , Second Quarter , Positive Topline Data , Syndrome Trial , Patient Enrolled , Recent Company , European Alliance , Syndrome Disease Activity Index , Syndrome Patient Reported Index , Pipeline Candidate , Autoimmune Diseases , Planned Expansion , Manufacturing Facility , Expanded Label , Include Co Administration , Biologics License Application , Dazodalibep Rheumatoid Arthritis , Key Upcoming Medical Meeting , American College , Key Medical Meetings , American Academy , Annual Meeting , Key Medical Meeting , European Committee , Multiple Sclerosis , Global Expansion , September In October , Sustainability Accounting Standards Board , That Care , Lupus Erythematosus , Areata Trial , Planned Phase , Nephritis Trial , Arthritis Trial , Transplant Rejection Trial , Segmental Glomerulosclerosis , Cutaneous Systemic Sclerosis Trial , Pivotal Phase , Pulmonary Fibrosis Trial , Gravis Trial , Related Disease Trial , Administration Trial , Cutaneous Systemic Sclerosis Exploratory Trial , Dermatitis Trial , Disease Trial , Infusion Duration Trial , Dosing Trial , Patented Medicines Prices Review Board , Segment Operating , Alkem Laboratories , Flow Statement , Balance Sheet , Regarding Use , Consolidated Statements , Consolidated Balance Sheets , Cash Flows , Earnings Per Share , Per Share , Per Share Basic , Operating Cash Flow , Rate Reconciliation , Three Months Ended September , Nine Months Ended September , Lake Forest , Corporation Finance , Vice President , Investor Relations Officer , Affairs Chief Communications Officer , Horizon , Herapeutics , Reports , Third , Quarter , 022 , Financial , Results , Increases , Bull , Ear , Sales , Djusted , Bitda , Guidance , Tepezza , Krystexxa , Beak , Nnual , Expectations ,